CDK4 and dedifferentiated liposarcoma: conducted a phase Ib proof-of-concept trial in which patients with advanced WDLPS and DDLPS received concomitant siremadlin, a selective MDM2 inhibitor, with ribociclib, a selective CDK4/6 inhibitor.